Fluticasone Propionate And Salmeterol Powder
Product Images NDC 68788-8453

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 68788-8453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fluticasone Prop Salmeterol Inh Powder 25050mcg (0dea4818 E9d6 42f2 A702 90419fff2695 00)

Label for fluticasone propionate and salmeterol inhalation powder 250/50 mcg. The label indicates it is a generic for Advair HFA and contains detailed information including the active ingredients and their strengths, manufacturing details by Hikma Pharmaceuticals USA Inc., storage warnings, and usage directions in English and Spanish. The label also features a barcode and a QR code, with sections for lot, batch, and insurance numbers left blank.*

FDA Label Image

Figurec.jpg (Figurec)

An instructional diagram showing two hands holding a respiratory inhaler device. The illustration includes a white directional arrow indicating a twisting motion, likely to demonstrate how to operate or activate the inhaler. A counter displaying the number 60 is visible on the device.*

FDA Label Image

Figuref.jpg (Figuref)

An instructional illustration showing how to hold and rotate a respiratory inhalation device with both hands. A large arrow indicates the direction to turn the blue-colored component on the side of the inhaler, which has a dose counter displaying the number 59.*

FDA Label Image

Figureh.jpg (Figureh)

Illustration of a respiratory inhalation device used for delivering fluticasone propionate and salmeterol powder. The diagram highlights a dosage indicator window showing the number 5 in red, likely representing remaining doses or a dose setting on the device's side.*

FDA Label Image

Fluticasone-propionate-chemical.jpg (Fluticasone Propionate Chemical)

Chemical structure of fluticasone propionate, one of the active ingredients in the combination powder inhalation product fluticasone propionate and salmeterol by Preferred Pharmaceuticals Inc.*

FDA Label Image

Figure-5-08172021.jpg (Image 03)

A line graph depicting the percent change in FEV1 over time for three groups: Fluticasone Propionate and Salmeterol Inhalation Powder 250 mcg/50 mcg, Fluticasone Propionate 250 mcg, and Placebo. The x-axis represents days and weeks from Day 1 to 24 weeks and endpoint, while the y-axis shows percent change in FEV1. The graph tracks patient counts at three intervals for each group.*

FDA Label Image

Figure-4.jpg (Image 04)

Line graph depicting the percentage change in FEV1 over 24 weeks and at endpoint for three groups: fluticasone propionate and salmeterol inhalation powder 250 mcg/50 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The y-axis shows % change in FEV1, and the x-axis shows weeks. Data points for each group are marked distinctly, showing trends over time in lung function change.*

FDA Label Image

Figure-1a (Image 05)

A line graph showing percent change in FEV1 over 12 weeks for different treatments: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily, fluticasone propionate 100 mcg twice daily, salmeterol 50 mcg twice daily, and placebo. The y-axis represents percent change in FEV1, and the x-axis represents weeks, with measurements from week 0 to week 12 and an endpoint. Four lines plotted with different markers correspond to each treatment group as indicated in the legend.*

FDA Label Image

Figure-2.jpg (Image 06)

A line graph showing the percentage change in FEV1 over 12 hours on the first treatment day for four groups: Fluticasone Propionate and Salmeterol Inhalation Powder 100 mcg/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone Propionate 100 mcg twice daily, and a placebo group. The x-axis represents hours, with baseline at hour 0, and the y-axis shows percentage change in FEV1 from 0% to 45%.*

FDA Label Image

Figure-3a (Image 07)

A line graph depicting the percent change in FEV1 relative to Day 1 baseline over 12 hours on the last treatment day (Week 12) for four groups: fluticasone propionate and salmeterol inhalation powder 100 mcg/50 mcg twice daily (triangles, N=73), salmeterol 50 mcg twice daily (circles, N=49), fluticasone propionate 100 mcg twice daily (squares, N=65), and placebo (diamonds, N=26). The y-axis shows percent change in FEV1, and the x-axis shows time in hours from baseline.*

FDA Label Image

Image1.jpg (Image1)

Illustration of the fluticasone propionate and salmeterol inhalation powder device showing labeled components including the mouthpiece, outer case, counter, thumb grip, and lever. The device label indicates a strength of 100 mcg/50 mcg and 60 blister count.*

FDA Label Image

Salmeterol-xinafoate-chemical.jpg (Salmeterol Xinafoate Chemical)

Chemical structure diagram depicting the molecular structures of fluticasone propionate and salmeterol, the active ingredients in the respiratory inhalation powder.*

FDA Label Image

Ww-image-2.jpg (Ww Image 2)

An instructional illustration showing hands holding a respiratory inhalation device for fluticasone propionate and salmeterol powder. The image features a dose counter displaying '60' and a circular arrow indicating a twisting or turning motion of the device, likely demonstrating how to prepare it for inhalation.*

FDA Label Image

Ww-image-4.jpg (Ww Image 4)

Illustration showing a person holding a respiratory inhaler device near their mouth, demonstrating use of a powder inhalation product for delivery of medication through inhalation.*

FDA Label Image

Ww-image-5.jpg (Ww Image 5)

Illustration showing a person using a respiratory inhaler device, placing it in their mouth for inhalation. The image demonstrates the proper technique for using an inhaler for pulmonary drug delivery.*

FDA Label Image

Ww-image-7.jpg (Ww Image 7)

An instructional illustration showing a person performing a mouth rinse and spit procedure over a sink. A glass with water is placed on the counter nearby. The person is depicted expelling liquid from their mouth, suggesting oral rinsing or spitting.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.